/INKT
INKT Stock - MiNK Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$11.59-1.95%
$0.23 (-1.95%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.32
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+202.0%upside
Target: $35.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INKT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.47 – $11.71
TARGET (TP)$35.00
STOP LOSS$10.66
RISK/REWARD1:25.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.35
52W High$76.00
52W Low$4.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-215,437 | $-204,617 | $-121,749 | $-77,960 | $-55,060 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-10,650,239 | $-22,921,105 | $-30,949,278 | $-18,606,296 | $-10,796,711 |
| Net Income | $-10,784,802 | $-22,457,859 | $-27,991,212 | $-30,212,770 | $-16,238,897 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.90 | $-6.54 | $-8.31 | $-9.03 | $-4.91 |
Company Overview
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$35
Average Target
↑ 202.0% Upside
Now
$35
Low
$35
Average
$35
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 15th 2025 | H.C. Wainwright | Upgrade | Buy | $35 |
| July 14th 2025 | William Blair | Downgrade | Market Perform | - |
Earnings History & Surprises
INKTBeat Rate
59%
Last 17 quarters
Avg Surprise
-6.5%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q1 24
-6.7%
$-1.60vs$-1.50
Q2 24
+31.3%
$-1.10vs$-1.60
Q3 24
+30.0%
$-0.70vs$-1.00
Q4 24
+37.5%
$-0.50vs$-0.80
Q1 25
-24.0%
$-0.62vs$-0.50
Q2 25
-14.8%
$-0.70vs$-0.61
Q3 25
-92.7%
$-1.06vs$-0.55
Q4 25
+24.4%
$-0.65vs$-0.86
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.68 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.86 | $-0.65 | +24.4% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.55 | $-1.06 | -92.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.61 | $-0.70 | -14.8% | ✗ MISS |
Q1 2025 | Mar 18, 2025 | $-0.50 | $-0.62 | -24.0% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.80 | $-0.50 | +37.5% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-1.00 | $-0.70 | +30.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.60 | $-1.10 | +31.3% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-1.50 | $-1.60 | -6.7% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.80 | $-1.50 | +16.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.90 | $-1.80 | +5.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-2.40 | $-1.70 | +29.2% | ✓ BEAT |
Q1 2023 | Mar 21, 2023 | $-2.10 | $-2.30 | -9.5% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-2.30 | $-1.90 | +17.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-2.40 | $-1.80 | +25.0% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-2.10 | $-2.30 | -9.5% | ✗ MISS |
Q1 2022 | Mar 18, 2022 | $-2.40 | $-1.80 | +25.0% | ✓ BEAT |
Q4 2021 | Nov 29, 2021 | $-0.20 | $-0.59 | -195.0% | ✗ MISS |
Q4 2021 | Oct 15, 2021 | — | $-0.22 | — | — |
Latest News
MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate
📉 NegativeBenzinga•Nov 14, 2025, 01:23 PM
MiNK Therapeutics Files For Mixed Shelf Offering Up To $150M
➖ NeutralBenzinga•Nov 7, 2025, 10:01 PM
MiNK Therapeutics Presents Updated Clinical Results Evaluating Agent-797, Alone And In Combination With Anti-PD-1 Therapy, In Patients With Advanced Solid Tumors Refractory To All Approved Treatments At SITC 2025
📈 PositiveBenzinga•Nov 7, 2025, 02:07 PM
MiNK Therapeutics Announces That Late-Breaking Phase 1 Data For Its Allogeneic iNKT Cell Therapy, AgenT-797, Will Be Presented At 40th Annual SITC Meeting Nov 7–9, 2025
📈 PositiveBenzinga•Oct 30, 2025, 01:03 PM
MiNK Therapeutics Extends Cash Runway
➖ NeutralThe Motley Fool•Aug 14, 2025, 06:45 PM
MiNK Therapeutics Cuts Q2 Cash Use 31%
📈 PositiveThe Motley Fool•Aug 14, 2025, 01:05 PM
Frequently Asked Questions about INKT
What is INKT's current stock price?
MiNK Therapeutics, Inc. (INKT) is currently trading at $11.59 per share. The stock has moved -1.95% today.
What is the analyst price target for INKT?
The average analyst price target for INKT is $35.00, based on 1 analyst.
What sector is MiNK Therapeutics, Inc. in?
MiNK Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INKT's market cap?
MiNK Therapeutics, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does INKT pay dividends?
No, MiNK Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
EQ
Equillium, Inc.
$1.15
Mkt Cap: $0.0B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
HOWL
Werewolf Therapeutics, Inc.
$0.69
Mkt Cap: $0.0B
IOBT
IO Biotech, Inc.
$0.66
Mkt Cap: $0.0B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
VTVT
vTv Therapeutics Inc.
$36.01
Mkt Cap: $0.1B
Explore stocks similar to INKT for comparison